

NEW PROTOCOL

Date received
12/6/13 (elec)



Signature Page for Human Research Review Protocols and Related Documentation

Use this signature page when submitting HRPO forms to your center-level Human Subjects Contact. When submitting materials with these forms, please consecutively number all pages, beginning with the protocol title page and followed by consent form(s) and ancillary documents. See *HRPO Guide: Overview* for further details. **NOTE: IRB (Institutional Review Board) refers to the NIOSH HSRB (National Institute for Occupational Safety and Health (NIOSH) Human Subjects Review Board (HSRB) of the CDC Human Research Protection Office (HRPO).**

1 Protocol identifiers

CAN# _____ (optional)

Leave protocol ID blank if not yet assigned.

CDC protocol ID: HSRB 13-OD-01XP Protocol version number _____ version date _____

Protocol title: Personal Floatation Devices and Commercial Fishermen: Evaluating Preconceptions and Use

Amendment number (if applicable): _____

2 Key CDC personnel

	Name and degrees (FirstName LastName, Degrees)	User ID	SEV #	CDC NC/division
Primary contact (required)	Christy Forrester, MS	cff6	1316	NIOSH/OD
Principal investigator (required)	Christy Forrester, MS	cff6	1316	NIOSH/OD

SEV # is CDC's Scientific Ethics Verification Number. CDC NC/division is the national center or equivalent and division or equivalent, or coordinating center or office if submitted at that level.

3 Forms submitted with this signature page

Check all that apply in the appropriate column.

IRB-reviewed protocols

- 0.1250: Initial Review by IRB
- 0.1251: Continuing Review of Approved Protocol
- 0.1252: Review of Changes to Approved Protocol
- 0.1254: Incident Report
- 0.1254S: Supplemental Adverse Event Report
- 0.1253: End of Human Research Review
- 0.1370: CDC's Research Partners
- 0.1371: CDC Rely on a Non-CDC IRB
- 0.1372: Outside Institution Rely on a CDC IRB
- 0.1373: CDC Cover an Individual Investigator

Exempted protocols

- 0.1250X: Initial Review for Exemption
- 0.1251X: Continuing Review of Exempted Protocol
- 0.1252X: Review of Changes to Exempted Protocol
- 0.1253: End of Human Research Review
- 0.1370: CDC's Research Partners

4 Signatures

As principal investigator, I hereby accept responsibility for conducting this CDC-sponsored research project in an ethical manner, consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants*, and to abide by the principles outlined in federal policies for the protection of human subjects at 45 CFR part 46, 21 CFR part 50, and 21 CFR part 56.

Signature	Date	Remarks
Principal CDC Investigator: <i>Cheryl L. Lomax</i>	<i>12/16/2013</i>	

As a supervisor of the principal investigator, I hereby accept responsibility for ensuring that this CDC-sponsored research project is conducted in an ethical manner, consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants*, and to abide by the principles outlined in federal policies for the protection of human subjects at 45 CFR part 46, 21 CFR part 50, and 21 CFR part 56.

Signature	Date	Remarks
Team Lead: <i>No Team Lead</i>		Check if PI is Team Lead: <input type="checkbox"/>
Branch Official (e.g., Chief or Senior Scientist): <i>No Branch Official</i>		Check if PI is Branch Official: <input type="checkbox"/>
Division Official (e.g., Director or ADS): <i>Fred Blaser</i>	<i>12/4/2013</i>	Check if PI is Division Official: <input type="checkbox"/>

I concur that this CDC-sponsored research project is consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants* and with other applicable CDC and national center policies.

Signature	Date	Remarks
Chair, NIOSH HSRB: <i>Mark Toracore</i>	<i>1-8-14</i>	<i>Waiver of Documentation of IC</i>

Other Clearance Official:
(e.g., Confidentiality Officer, Coordinating Center/Office Official)

Expedited Review; Minimal Risk; as provided for in 45CFR 46.110 (b)(1) category(s) 7

5 Additional comments

Approved for one year; Renewal date 1-8-2015;
 CDC 0.1250 form estimated subject # is 400;
 Subject # to date is _____;
 Approved/Amended Total Subject # is 400.

6 Reminder regarding other regulatory clearance processes

The principal investigator is responsible for obtaining other regulatory reviews as needed, which may include OMB clearance under the Paperwork Reduction Act (PRA) for federally sponsored information collections. Approval by or exemption from the IRB is unrelated to OMB clearance requirements under the PRA. For more information on whether your study requires clearance under PRA or other regulations, please consult the appropriate officials within your national center.

APPROVED